search results for 
Logo

Compensation of the Management Board

The entire Supervisory Board of Fresenius Management SE is responsible for determining the compensation of the Management Board. The Supervisory Board is assisted in this task by a personnel committee. In the year under review, the acting personnel committee was composed of Dr. Gerd Krick, Dr. Dieter Schenk and Dr. Karl Schneider.

The Management Board compensation system was reviewed by an independent external compensation expert in the fiscal year 2010 and later submitted to the Annual General Meeting of Fresenius SE (since January 28, 2011: Fresenius SE & Co. KGaA) for approval. On May 12, 2010, the Annual General Meeting approved of the Management Board compensation system with a majority of 99.51% of the votes cast. In 2011, it was complemented by a share-based compensation with cash settlement (performance shares) in order to strengthen the component with long-term incentive effects. The amended Management Board compensation system was reviewed by an independent external compensation expert and will be submitted to the Annual General Meeting on May 11, 2012 for approval.

The objective of the compensation system is to enable the members of the Management Board to participate reasonably in the sustainable development of the Company’s business with the compensation paid and to reward them based on their duties and performance as well as their successes in managing the Company’s economic and the financial position while giving due regard to the peer environment.

The compensation of the Management Board is, as a whole, performance-oriented and was composed of three elements in the fiscal year 2011:

  • non-performance-related compensation (basic salary)
  • performance-related compensation (variable bonus)
  • components with long-term incentive effects (stock options, postponed bonus payments and share-based compensation with cash settlement (performance shares))

In addition, six members of the Management Board had pension commitments in the reporting period.

The design of the individual components is based on the following criteria:

The non-performance-related compensation was paid in twelve monthly installments as basic salary in the fiscal year 2011. Moreover, the members of the Management Board received additional benefits consisting mainly of insurance premiums, the private use of company cars, special payments such as rent supplements and reimbursement of certain other charges as well as contributions to pension and health insurance.

The performance-related compensation will also be granted for the fiscal year 2011 as a short-term cash component (annual bonus) and as a longer-term compensation component (stock options, postponed bonus payments, share-based compensation with cash settlement (performance shares)). The amount of the bonus in each case is dependent on certain target parameters oriented on the net income attributable to Fresenius SE & Co. KGaA and/or to the relevant business segments being achieved. In the case of the members of the Management Board with functional responsibility for the entire Group – such members being Dr. Schneider, Mr. Sturm and Dr. Götz –, the amount of the variable bonus is based in its entirety on the respective net income attributable to Fresenius SE & Co. KGaA (after deduction of noncontrolling interest). For Mr. Baule and Dr. De Meo, half of the amount of the variable bonus in each case depends on the development of the net income attributable to Fresenius SE & Co. KGaA as well as the development of the net income of the business segment (in each case after deduction of noncontrolling interest) for which the respective member of the Management Board is responsible. Half of the amount of the variable bonus of Dr. Wastler in each case is oriented on the net income attributable to Fresenius SE & Co. KGaA (after deduction of noncontrolling interest) as well as on the net income before tax and extraordinary income/expenditures of the VAMED group. Dr. Lipps receives his compensation exclusively from Fresenius Medical Care. Furthermore, the Supervisory Board may grant a discretionary bonus for extraordinary performance.

For the fiscal years 2011 and 2010, the amount of cash payment of the Management Board of the general partner of Fresenius SE & Co. KGaA consisted of the following:


  Non-performance-related compensation Performance-related compensation Cash compensation (without long-term incentive components)
  Salary Other2 Bonus  
1 Dr. Ben Lipps receives his compensation only from Fresenius Medical Care, of which Fresenius SE & Co. KGaA held 30% of the total subscribed capital. As Dr. Ben Lipps is a member of the Management Board of Fresenius Management SE, his compensation has to be included in the compensation report of the Fresenius Group.
2 Includes insurance premiums, private use of company cars, contributions to pension and health insurance as well as other benefits.
€ in thousands 2011 2010 2011 2010 2011 2010 2011 2010
Dr. Ulf M. Schneider 900 900 61 47 1,150 908 2,111 1,855
Rainer Baule 500 500 120 42 764 608 1,384 1,150
Dr. Francesco De Meo 500 500 19 18 671 498 1,190 1,016
Dr. Jürgen Götz 375 375 33 30 584 464 992 869
Dr. Ben Lipps1 862 905 182 354 1,078 1,172 2,122 2,431
Stephan Sturm 500 500 86 85 721 574 1,307 1,159
Dr. Ernst Wastler 425 425 33 32 571 461 1,029 918
Total 4,062 4,105 534 608 5,539 4,685 10,135 9,398

  Non-performance-related compensation Performance-related compensation Cash compensation (without long-term incentive components)
  Salary Other2 Bonus  
1 Dr. Ben Lipps receives his compensation only from Fresenius Medical Care, of which Fresenius SE & Co. KGaA held 30% of the total subscribed capital. As Dr. Ben Lipps is a member of the Management Board of Fresenius Management SE, his compensation has to be included in the compensation report of the Fresenius Group.
2 Includes insurance premiums, private use of company cars, contributions to pension and health insurance as well as other benefits.
€ in thousands 2011 2010 2011 2010 2011 2010 2011 2010
Dr. Ulf M. Schneider 900 900 61 47 1,150 908 2,111 1,855
Rainer Baule 500 500 120 42 764 608 1,384 1,150
Dr. Francesco De Meo 500 500 19 18 671 498 1,190 1,016
Dr. Jürgen Götz 375 375 33 30 584 464 992 869
Dr. Ben Lipps1 862 905 182 354 1,078 1,172 2,122 2,431
Stephan Sturm 500 500 86 85 721 574 1,307 1,159
Dr. Ernst Wastler 425 425 33 32 571 461 1,029 918
Total 4,062 4,105 534 608 5,539 4,685 10,135 9,398

In the fiscal year 2011, the directly paid bonus, excluding the payment to Dr. Ben Lipps, amounts to €4,461 thousand. This equals 95% of the total bonus of €4,691 thousand. The remaining part in an amount of €230 thousand was converted into a component based on a multi-year assessment and the payment was postponed by two years.

To ensure that the overall system of compensation of the members of the Management Board is oriented towards long-term and sustained corporate development, the compensation system provides that the share of long-term variable compensation components is at least equal in its amount to half of the total variable compensation components granted to the respective member of the Management Board. As a means of ensuring this minimum ratio in favor of the compensation components oriented towards the long term, it is expressly provided that the Supervisory Board may determine that the variable bonus to be paid as a rule annually is converted (pro rata) into a variable compensation component based on a multi-year assessment in order to also take account of any negative developments within the assessment period. This is done in such a way that the maturity of the yearly bonus earned on a variable basis is postponed at the discretion of the Supervisory Board, either on a pro rata basis or in its entirety, by two years. At the same time, it is ensured that any payment is made to the member of the Management Board after expiry of such multi-year period only if (i) no subsequent adjustment of the decisive (i. e. adjusted by extraordinary effects) net income attributable to Fresenius SE & Co. KGaA (after deduction of noncontrolling interest) beyond an amount equal to a tolerance range of 10% is made, and (ii) the amount of net income attributable to Fresenius SE & Co. KGaA (adjusted for extraordinary effects) in the two relevant subsequent years is not substantially less than the net income attributable to Fresenius SE & Co. KGaA (adjusted by extraordinary effects, after deduction of noncontrolling interest) of the respective preceding fiscal years. In the event of the aforementioned conditions for payment being missed only to a minor and/or partial extent, the Supervisory Board may resolve on a corresponding pro rata payment of the converted portion of the variable bonus. No interest is payable on the converted bonus claim from the time when it first arises until the time of its effective payment. In this way, the variable bonus can be converted pro rata or in its entirety into a genuine variable compensation component on a multi-year assessment basis which also participates in any negative developments during the relevant assessment period.

The system of compensation for the Management Board moreover provides for a contractually stipulated cap or possibility of capping the amount of the annual compensation to be claimed by the member of the Management Board overall, i. e. including all variable compensation components. This makes it possible to adequately take account in particular of those extraordinary developments which are not in any relevant proportion to the performance of the Management Board.

Under the compensation system, the amount of the basic and the total compensation of the members of the Management Board was and will be assessed giving particular regard to the relevant comparison values of other DAX companies and similar companies of comparable size and performance from the relevant industrial sector.

In the fiscal year 2011, stock options based on the Stock Option Plan 2008 of Fresenius SE & Co. KGaA and the Fresenius Medical Care AG & Co. KGaA Stock Option Plan 2011 as well as a share-based compensation with cash settlement were granted as components with long-term incentive effects. The number of stock options to be granted is defined in each case by the Supervisory Board at its discretion, with all members of the Management Board, except for the Chairman of the Management Board who receives double the number of stock options, receiving the same number of stock options.

The principles of both plans are described in more detail in note 34 of the notes of the Fresenius Group, Stock options.

In the fiscal year 2011, as a further long-term incentive component, the members of the Management Board were granted an entitlement to a share-based compensation with cash settlement (performance shares) for the first time.

The entitlement is subject to a four-year vesting period although a shorter period may apply in special cases (e. g. professional incapacity, retirement, non-renewal of expired service agreements by the Company). The amount of cash payment corresponds to the share price of Fresenius SE & Co. KGaA’s ordinary shares upon exercise at the end of the four-year vesting period.

The payment is subject to the achievement of the performance target of an 8% increase of the consolidated net income attributable to Fresenius SE & Co. KGaA (adjusted for extraordinary effects) year over year during the four-year vesting period. For each year in which the success target has not been met, one-fourth of the entitlement shall forfeit. Apart from that, the total entitlement for payment is earned if an average increase of the consolidated net income attributable to Fresenius SE & Co. KGaA of 8% is achieved over the four-year vesting period.

For the fiscal years 2011 and 2010, the number and value of stock options issued, the value of the postponed performance-related compensation as well as the value of the share-based compensation with cash settlement (performance shares) is shown in the following table.

The stated values of the stock options granted to members of the Management Board in the fiscal year 2011 correspond to their fair value at the time of grant, namely a value of €19.10 (2010: €12.92) per stock option of Fresenius SE & Co. KGaA and €13.44 (2010: €8.07) per stock option of FMC-AG & Co. KGaA. The exercise price of the granted stock options of Fresenius SE & Co. KGaA was €71.28 (2010: €53.44).

As the financial targets of the year 2011 were achieved, Dr. Ben Lipps is entitled to a share-based compensation in an amount of €684 thousand (2010: €391 thousand) in accordance with the bonus agreement of Fresenius Medical Care. The entitlement is based on the development of the ordinary share of Fresenius Medical Care and has a three-year vesting period.

LONG-TERM INCENTIVE COMPONENTS


  Stock options1 Postponed performance-related compensation Share-based compensation with cash settlement (performance shares) Total
  Number Value, € in thousands Value, € in thousands Value, € in thousands Value, € in thousands
  2011 2010 2011 2010 2011 2010 2011 2010 2011 2010
1 Stock options that were granted in 2011 and 2010 under the Fresenius SE & Co. KGaA stock option plan. Dr. Ben Lipps received stock options under the Fresenius Medical Care stock option plan.
Dr. Ulf M. Schneider 56,760 56,760 1,084 733 0 174 100 0 1,184 907
Rainer Baule 28,380 28,380 542 367 122 241 100 0 764 608
Dr. Francesco De Meo 28,380 28,380 542 367 29 131 100 0 671 498
Dr. Jürgen Götz 28,380 28,380 542 367 0 98 100 0 642 465
Dr. Ben Lipps 74,700 99,600 1,004 804 0 0 684 391 1,688 1,195
Stephan Sturm 28,380 28,380 542 367 79 208 100 0 721 575
Dr. Ernst Wastler 28,380 28,380 542 367 0 95 100 0 642 462
Total 273,360 298,260 4,798 3,372 230 947 1,284 391 6,312 4,710

  Stock options1 Postponed performance-related compensation Share-based compensation with cash settlement (performance shares) Total
  Number Value, € in thousands Value, € in thousands Value, € in thousands Value, € in thousands
  2011 2010 2011 2010 2011 2010 2011 2010 2011 2010
1 Stock options that were granted in 2011 and 2010 under the Fresenius SE & Co. KGaA stock option plan. Dr. Ben Lipps received stock options under the Fresenius Medical Care stock option plan.
Dr. Ulf M. Schneider 56,760 56,760 1,084 733 0 174 100 0 1,184 907
Rainer Baule 28,380 28,380 542 367 122 241 100 0 764 608
Dr. Francesco De Meo 28,380 28,380 542 367 29 131 100 0 671 498
Dr. Jürgen Götz 28,380 28,380 542 367 0 98 100 0 642 465
Dr. Ben Lipps 74,700 99,600 1,004 804 0 0 684 391 1,688 1,195
Stephan Sturm 28,380 28,380 542 367 79 208 100 0 721 575
Dr. Ernst Wastler 28,380 28,380 542 367 0 95 100 0 642 462
Total 273,360 298,260 4,798 3,372 230 947 1,284 391 6,312 4,710

At the end of the fiscal year 2011, the members of the Management Board held a total of 1,050,050 (2010: 978,960) stock options and convertible bonds (together referred to as stock options) of Fresenius SE & Co. KGaA and 572,700 (2010: 598,870) stock options and convertible bonds of FMC-AG & Co. KGaA.

The development and the status of the stock options of the Management Board in the fiscal year 2011 are shown in the following table:


  Dr. Ulf M. Schneider Rainer Baule Dr. Francesco De Meo Dr. Jürgen Götz Dr. Ben Lipps1 Stephan Sturm Dr. Ernst Wastler Total2
1 Dr. Ben Lipps holds stock options under the Fresenius Medical Care stock option plan.
2 Only stock options of Fresenius SE & Co. KGaA, excluding stock options of Dr. Ben Lipps
Options outstanding on January 1, 2011                
number 335,400 167,700 109,980 87,300 598,870 167,700 110,880 978,960
average exercise price in € 42.51 42.51 48.41 48.90 32.15 43.63 46.44 44.38
Options granted during fiscal year      
number 56,760 28,380 28,380 28,380 74,700 28,380 28,380 198,660
average exercise price in € 71.28 71.28 71.28 71.28 52.48 71.28 71.28 71.28
Options exercised during fiscal year                
number 58,480 65,790 0 0 100,870 0 3,300 127,570
average exercise price in € 24.48 30.95     18.54   22.81 27.77
average stock price in € 72.65 69.18     49.22   71.20 70.82
Options outstanding on December 31, 2011                
number 333,680 130,290 138,360 115,680 572,700 196,080 135,960 1,050,050
average exercise price in € 50.37 54.37 52.72 53.98 37.20 47.26 51.83 51.18
average remaining life in years 4.9 5.1 5.1 5.1 4.1 4.7 5.0 5.0
range of exercise prices in € 29.50 to 71.28 33.81 to 71.28 33.81 to 71.28 33.81 to 71.28 30.49 to 52.48 29.50 to 71.28 29.50 to 71.28 29.50 to 71.28
Exercisable options on December 31, 2011                
number 168,560 47,730 55,800 33,120 298,800 113,520 53,400 472,130
average exercise price in € 47.35 55.95 51.63 55.30 33.30 42.76 49.34 48.40

  Dr. Ulf M. Schneider Rainer Baule Dr. Francesco De Meo Dr. Jürgen Götz Dr. Ben Lipps1 Stephan Sturm Dr. Ernst Wastler Total2
1 Dr. Ben Lipps holds stock options under the Fresenius Medical Care stock option plan.
2 Only stock options of Fresenius SE & Co. KGaA, excluding stock options of Dr. Ben Lipps
Options outstanding on January 1, 2011                
number 335,400 167,700 109,980 87,300 598,870 167,700 110,880 978,960
average exercise price in € 42.51 42.51 48.41 48.90 32.15 43.63 46.44 44.38
Options granted during fiscal year      
number 56,760 28,380 28,380 28,380 74,700 28,380 28,380 198,660
average exercise price in € 71.28 71.28 71.28 71.28 52.48 71.28 71.28 71.28
Options exercised during fiscal year                
number 58,480 65,790 0 0 100,870 0 3,300 127,570
average exercise price in € 24.48 30.95     18.54   22.81 27.77
average stock price in € 72.65 69.18     49.22   71.20 70.82
Options outstanding on December 31, 2011                
number 333,680 130,290 138,360 115,680 572,700 196,080 135,960 1,050,050
average exercise price in € 50.37 54.37 52.72 53.98 37.20 47.26 51.83 51.18
average remaining life in years 4.9 5.1 5.1 5.1 4.1 4.7 5.0 5.0
range of exercise prices in € 29.50 to 71.28 33.81 to 71.28 33.81 to 71.28 33.81 to 71.28 30.49 to 52.48 29.50 to 71.28 29.50 to 71.28 29.50 to 71.28
Exercisable options on December 31, 2011                
number 168,560 47,730 55,800 33,120 298,800 113,520 53,400 472,130
average exercise price in € 47.35 55.95 51.63 55.30 33.30 42.76 49.34 48.40

The following table shows the total compensation of the Management Board of the general partner of Fresenius SE & Co. KGaA for the years 2011 and 2010:

  Cash compensation (without long-term incentive components) Long-term incentive components Total compensation (including long-term incentive components)
€ in thousands 2011 2010 2011 2010 2011 2010
Dr. Ulf M. Schneider 2,111 1,855 1,184 907 3,295 2,762
Rainer Baule 1,384 1,150 764 608 2,148 1,758
Dr. Francesco De Meo 1,190 1,016 671 498 1,861 1,514
Dr. Jürgen Götz 992 869 642 465 1,634 1,334
Dr. Ben Lipps 2,122 2,431 1,688 1,195 3,810 3,626
Stephan Sturm 1,307 1,159 721 575 2,028 1,734
Dr. Ernst Wastler 1,029 918 642 462 1,671 1,380
Total 10,135 9,398 6,312 4,710 16,447 14,108

  Cash compensation (without long-term incentive components) Long-term incentive components Total compensation (including long-term incentive components)
€ in thousands 2011 2010 2011 2010 2011 2010
Dr. Ulf M. Schneider 2,111 1,855 1,184 907 3,295 2,762
Rainer Baule 1,384 1,150 764 608 2,148 1,758
Dr. Francesco De Meo 1,190 1,016 671 498 1,861 1,514
Dr. Jürgen Götz 992 869 642 465 1,634 1,334
Dr. Ben Lipps 2,122 2,431 1,688 1,195 3,810 3,626
Stephan Sturm 1,307 1,159 721 575 2,028 1,734
Dr. Ernst Wastler 1,029 918 642 462 1,671 1,380
Total 10,135 9,398 6,312 4,710 16,447 14,108

The stock options and the entitlement to a share-based compensation (performance shares) can be exercised only after the expiry of the specified vesting period. Their value is recognized over the vesting period as expense in the respective fiscal year. The expenses attributable to the fiscal years 2011 and 2010 are stated in the following table.

EXPENSES FOR LONG-TERM INCENTIVE COMPONENTS


  Stock options Share-based compensation with cash settlement (performance shares) Total expenses for share-based compensation
€ in thousands 2011 2010 2011 2010 2011 2010
Dr. Ulf M. Schneider 736 681 2 0 738 681
Rainer Baule 368 341 2 0 370 341
Dr. Francesco De Meo 351 268 2 0 353 268
Dr. Jürgen Götz 368 327 2 0 370 327
Dr. Ben Lipps 1,098 879 780 860 1,878 1,739
Stephan Sturm 368 341 2 0 370 341
Dr. Ernst Wastler 351 268 2 0 353 268
Total 3,640 3,105 792 860 4,432 3,965

  Stock options Share-based compensation with cash settlement (performance shares) Total expenses for share-based compensation
€ in thousands 2011 2010 2011 2010 2011 2010
Dr. Ulf M. Schneider 736 681 2 0 738 681
Rainer Baule 368 341 2 0 370 341
Dr. Francesco De Meo 351 268 2 0 353 268
Dr. Jürgen Götz 368 327 2 0 370 327
Dr. Ben Lipps 1,098 879 780 860 1,878 1,739
Stephan Sturm 368 341 2 0 370 341
Dr. Ernst Wastler 351 268 2 0 353 268
Total 3,640 3,105 792 860 4,432 3,965

QUICKFINDER

History

External related links

Tools